Category A threat focus
The program addresses a high-consequence pathogen with no approved countermeasure — a core criterion for federal medical countermeasure investment.
Pipeline
A lead program aimed at an unmet biodefense need
KNX-001 targets Hantavirus Pulmonary Syndrome caused by Andes virus — a CDC Category A priority pathogen with no approved vaccines or therapeutics.
| Program | Pathogen | Indication | Stage | Funding Pathway |
|---|---|---|---|---|
| KNX-001 | Andes Virus (ANDV) | Hantavirus Pulmonary Syndrome (HPS) | Preclinical | BARDA NIH |
Swipe the table horizontally to see all columns.
35–40%
Reported case fatality rate for HPS
Zero
Approved vaccines or therapeutics
Category A
CDC biodefense priority pathogen class
Preclinical
Current stage of KNX-001
Indication
Hantavirus Pulmonary Syndrome
HPS is a severe respiratory illness caused by New World hantaviruses, of which Andes virus (ANDV) is among the most consequential. There are no approved vaccines or therapeutics, and the reported case fatality rate is 35–40%.
ANDV is classified as a CDC Category A biodefense priority — the tier reserved for agents that pose the highest risk to national security because they can be disseminated, cause high mortality, and require special public health preparedness.
Kinexar's pAMP-based HPS vaccine candidate is designed to elicit broad neutralizing antibody and T-cell responses, combining multi-epitope coverage with a thermostable, non-replicating format suited to national stockpiling.
KNX-001
Program profile
- Platform
- pAMP concatemeric peptide (DNA-FACE)
- Pathogen
- Andes virus (ANDV)
- Indication
- Hantavirus Pulmonary Syndrome (HPS)
- Stage
- Preclinical
- Immune objective
- Broad neutralizing antibody and T-cell responses
- Funding pathway
- BARDA, NIH
Funding Pathway
BARDA and NIH alignment
KNX-001 is being advanced with federal medical countermeasure priorities in mind, from candidate selection through manufacturing strategy.
Stockpile-ready format
Thermostable, non-replicating constructs reduce cold-chain burden, supporting national stockpile and field-deployment scenarios.
Manufacturable at scale
Standard recombinant protein production avoids live-virus handling and specialized biologics infrastructure, simplifying surge capacity planning.
Preclinical package
Immunogenicity and protection studies are structured to generate the data expected for federal non-clinical development milestones.
Platform leverage
Because pAMP is modular, success against ANDV establishes a route to additional priority pathogens using the same technology base.
Grant execution
Kinexar Bio is actively pursuing BARDA and NIH funding, with scientific leadership dedicated to grant strategy and submission.
Program officers and partners welcome
Contact us for program detail, preclinical plans, and collaboration opportunities around KNX-001 and the pAMP platform.